Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

Table 1 Effect of rosiglitazone pre-treatment on cisplatin-induced nephrotoxicity in chemically induced breast cancer model

	Change in Body weight (g)	BUN (mg/dl)	Creatinine (mg/kg)	Albumin (g/dl)
Normal control	11.00 ± 3.37	33 ± 3.78	1.02 ± 0.08	3.59 ± 0.03
Breast cancer control	3.00 ± 3.12	36 ± 3.53	1.07 ± 0.12	3.73 ± 0.12
Rosi (8 mg/kg)	8.00 ± 3.49	28 ± 2.85	0.93 ± 0.05	3.58 ± 0.09
Cis (7.5 mg/kg)	-35.00 ± 2.52***^a	318 ± 14.20***^a	5.52 ± 0.35***^a	2.94 ± 0.14***^a
PT Rosi (8 mg/kg) + Cis (7.5 mg/kg)	-6.00 ± 2.33***^b	167 ± 14.41***^b	1.96 ± 0.23***^b	3.73 ± 0.20***^b

All the values are expressed as mean ± SEM (n = 8). ***P < 0.001, a Vs Cancer Control & b Vs Cisplatin. Where, Rosi is rosiglitazone, Cis is cisplatin and PT is pretreatment

ISSN: 1471-2407